104
Views
3
CrossRef citations to date
0
Altmetric
Original Research

A bibliometric analysis of the 100 most influential papers on COPD

, , , , &
Pages 667-676 | Published online: 25 Mar 2015

Abstract

Objective

We aimed to identify the 100 top-cited articles published on chronic obstructive pulmonary disease (COPD) and to analyze their characteristics so as to provide information on the achievement and development in COPD research over the past decades.

Methods and materials

A comprehensive list of citation classics in COPD was generated by searching the Science Citation Index expanded database, using the keywords “COPD” or “chronic obstructive pulmonary disease” or “chronic obstructive pulmonary diseases”. The 100 top-cited research papers were retrieved by reading the abstract or full text if needed. All eligible articles were read for basic information, including country of origin, organizations, article type, journals, research field, and authors.

Results

The 100 top-cited articles on COPD were published between 1966 and 2010. The number of citations ranged from 254 to 2,164, with a mean of 450 citations for each article. These citation classics were from 32 countries, with 38 from the United States. The Imperial College London led the list of classics, with 16 papers. The 100 top-cited articles were distributed in 18 journals, with the American Journal of Respiratory, Critical Care Medicine, and Journal of the American Medical Association topping the list. Among the various fields, both respiratory system (63%) and general internal medicine (63%) were the most common fields of study for the 100 articles.

Conclusion

Our bibliometric analysis provides a historical perspective on the progress of scientific research on COPD. Articles originating from the United States and published in high-impact specialized respiratory journals are most likely to be cited in the field of COPD research.

Introduction

Chronic obstructive pulmonary disease (COPD) continues to be an important cause of morbidity, mortality, and health care costs worldwide. As the global population ages, the burden of COPD will increase in the years to come.Citation1Citation3 Numerous specialists and researchers have focused their efforts on COPD in an attempt to gain a better understanding of how comorbid diseases, different phenotypes, and risk factor affect the outcome of COPD patients. A great numbers of articles have been published annually and have given new insights into the mechanism or treatment of COPD.Citation4Citation6 However, there still exists a lack of knowledge regarding the quality of scientific yield in relation to this area.

It is generally believed that publications represent the central part of a research process. In medicine, the number of times a paper is cited by other authors has been established as a widely used and logical measure of how much academic influence it has had in its subject area. The reporting of this type of citation analysis is widespread in the medical literature.Citation7Citation16 One way to measure the academic importance of an article is the rate at which the work is quoted or referenced by other authors.Citation7,Citation11,Citation16 The article referenced by another peer-reviewed article receives a “citation.” The total number of citations that an article receives is not necessarily a measure of its academic quality or even its influence upon the practice of the author’s or authors’ peers.Citation17 Nevertheless, it does testify to the readership of the particular article and the influence of the article in generating changes in practice, controversy, discussion, or further research. Citation is viewed as a direct measure of the recognition an article has received in its field. Citation analysis in specific journals and specific subject areas has become a popular method to assess the citation impact of a journal, article, or author.Citation8,Citation10Citation13,Citation18Citation23

The Institute for Scientific Information (ISI) has been collecting citation and other academic impact information since 1945 and has been available electronically since 1979. ISI (now a subsidiary of Thomson Corp) calls their newest journal citation system “Science Citation Index® (SCI) Expanded,” and it is one of the databases available under the banner of Web of Science. Citation data from peer-reviewed articles are indexed from more than 10,000 high-impact journals, not only from the sciences and social sciences but also, from the arts and humanities.

This search used the electronic version of this database to determine which published articles in medical journals have been cited most often by other authors, by ranking the 100 top-cited works. By analyzing characteristics of these articles, we intended to determine what qualities make a COPD article important to the specialty.

Materials and methods

On June 30, 2014, authors searched Web of Science and identified the 100 top-cited articles relating to COPD () published in professional journals from 1945 to date. The articles entitled using the terms “COPD” or “chronic obstructive pulmonary disease” or “chronic obstructive pulmonary diseases” were included in the research.

Table 1 The 100 most cited papers in COPD

Each article in the most cited 100 was reviewed, and the basic information collected included authors, year of publications, source journal of the article, geographic origin of the authors, and study field (general internal medicine, respiratory system, cardiovascular system cardiology, immunology, microbiology, physiology, research experimental medicine, sports science, or surgery). The full texts were mainly selected by PubMed or ScienceDirect. In addition, other methods were also used to search for articles that were not found in the aforementioned database, for example, interlibrary lending and requests for help on the PubMed.cn website (http://paper.pubmed.cn/). This website is a Chinese language–based platform used by scholars to request and share literatures. Several articles were cited more often than others because of the difference in time since publication. Thus, a citation index was also determined for each article to control this error. The citation index was defined as the mean number of citation times per year.

Statistical analysis was performed using SPSS 17 (SPSS Inc., Chicago, IL, USA). Spearman correlation analysis was used to test the total citation times and number of citation times per year, with an alpha level of 0.05. Descriptive statistics were quantified as counts or percentages of parameters.

As this was a bibliometric analysis, it was not necessary to obtain Internal Review Board approval.

Results

A total of 22,210 papers were identified in the initial search for the period from 1960 to present, with 12,098 published as “article” and 1,436 classified as “review”. Among them, 623 articles were cited more than 100 times. One hundred selected articles were published from 1966 to 2010, of which about 55% were published after 2000. The mean number of citations was 450 (range 254 to 2,164), and seven papers were cited more than 1,000 times (). Annual average number of citations were correlated by total number of citations (rs=0.659, P<0.0001).

The most cited paper, published by Rabe et alCitation24 in 2007, was an executive summary describing the global strategy for the diagnosis, management, and prevention of COPD. Interestingly, the second most cited paper, by Celli et alCitation25 received 1,659 citations and was also a summary of standards for the diagnosis and treatment of patients with COPD, published in 2004. The third article, by Hogg et alCitation26 was a randomized controlled trial (RCT) – the paper proved that 1) progression of COPD is associated with the accumulation of inflammatory mucous exudates in the lumen and infiltration of the wall by innate and adaptive inflammatory immune cells that form lymphoid follicles, and 2) these changes are coupled to a repair or remodeling process that thickens the walls of these airways. The most recent paper came from 2010 and was cited 367 times. This paperCitation27 proposed use of the “frequent exacerbation phenotype” to predict COPD exacerbations, implicating an important target of exacerbation-prevention strategies across the spectrum of disease severity. The last paper on the most cited list was a cohort study, authored by Marquis et al from 2002 and cited 254 times to date, which found that the midthigh muscle cross-sectional area was a better predictor of mortality than body mass index (BMI) in COPD patients; these findings suggest that the assessment of body composition may be useful in clinical practice.Citation28

The 100 top-cited articles were published in 18 journals, predominantly in American Journal of Respiratory and Critical Care Medicine (n=30), followed by European Respiratory Journal (n=14) and New England Journal of Medicine (n=12) ().

Table 2 Top-ten sources that contribute most articles to the top-100 papers

The greatest number of top-cited articles were published in 1996, 2000, and 2002 (n=8 each). The least number of articles was published in the 1960s (n=1 [decade]). Articles on the list were divided into three periods, 1960 to 1989 (n=8), 1990 to 1999 (n=37), and after 2000 (n=55) ().

Table 3 Decades distribution of the top-100 most cited papers

The country origins of the articles included: the United States (n=38), England (n=34), Canada (n=20), Netherlands (n=12), Italy (n=10), Belgium (n=9), Spain (n=8), Denmark (n=7), Australia (n=6), and Scotland (n=5). The rest of the countries had less than five publications. shows the distribution of top-cited articles over the countries of origin. Given some articles were authored with multiple sources of origin, especially those in the form of international research collaborations, the total number of countries of origin exceeded 100. The leading institutions are shown in . Imperial College London was found to be the most productive institution (n=16), followed by the University of London (n=10) and GlaxoSmithKline (n=9).

Table 4 Countries that contributed more than four papers in the 100 most influential papers

Table 5 The top-ten institutions contributing to the most cited articles in COPD

Among the 100 top-cited articles in COPD, the overwhelming majority (n=63 each) were studies belonging to “general internal medicine” and “respiratory system”, followed by two studies in “cardiovascular system cardiology”. Other fields, like “immunology”, “microbiology” and “physiology” only had one article each ().

Table 6 Research field of the most cited articles in COPD

The top-cited papers were written by 749 authors and ranged from 1 to 70 per article. Three articles had one author, followed by eight articles with two authors, and eight articles with three authors. presents a list of the most productive authors, showing that Barnes and Wedzicha each authored ten articles, followed by Vestbo (n=8), Jones (n=7), Buist (n=6), Calverley (n=6), Hogg (n=6), Anthonisen (n=5), Celli (n=5), Maltais (n=5), and Seemungal (n=5) ().

Table 7 The authors who contribute more than four articles to the top-100 papers

Discussion

In medical literature, the number of times other authors reference an article is one measure of the influence of the publication, and this type of citation analysis strategy is widely used as a bibliometric study. The evaluation of specialty-wide citation analyses has been reported in other areas of medicine.Citation7Citation9,Citation18Citation21,Citation23 However, the establishment of a citation rank list across a specialty, comprising many journals specific to an area of medicine, is a more complex process than citation analysis for one journal, although such analyses have been reported in some other areas of medicine.Citation31Citation34

In this review, researchers ranked the top 100 articles by number of citations, in the specialty of COPD. The top article had 2,164 citations. Seven papers were cited more than 1,000 times, of which three were summaries of the most well-known international COPD management guidelines, by different research institutions or in different periods. However, they all represented the latest achievements of COPD development in their period and have played profound influence in COPD treatment and research development around the world. While the third-place paper was classic RCT research, the findings created a new therapy targets for COPD treatment. The fourth paper also was classic; the authors proved a multidimensional grading system (the BODE [BMI, airflow obstruction, dyspnea, and exercise] index) assessing the respiratory and systemic expressions of COPD would better categorize and predict outcome in COPD patients than the forced expiratory volume in one second (FEV1). The fifth and sixth papers were specialized in the exploration of COPD drug therapy, and both of their groundbreaking discoveries have provided new directions for COPD treatment. In sum, the main reason for being so widely referenced is that the findings or conclusions reported in these papers have produced historical influence in COPD treatment and research history. However, every article on the list can be considered a citation “classic” by the frequently used, but somewhat arbitrary, marker of 100 pieces as the benchmark.Citation29

This review of the most cited articles in COPD may be worthwhile for several reasons. First, the observations suggest the authors of citation classics in COPD have produced more highly cited articles than many of their colleagues in other specialties. Second, this study has successfully identified several attributes of articles in citation, indicating that journal and country of origin are very important factors. Finally, this paper might be considered as the first report on the most cited papers in COPD.

The study characteristics revealed here echo those found in similar reviews. The majority of articles originated in the United States. This result is in line with previous studies and is in accordance with the reported strong influence of the United States in research related to health science,Citation8,Citation12,Citation14 indicating that American authors may be at an advantage. On the contrary, in Asian countries, although the scientific research has achieved rapid development in recent years, authors did not have a place in the COPD research field since their contribution in research productivity was rather disappointing. European countries, like England, Netherlands, Italy, etc, also showed a higher productivity. This finding seems to conform to the phenomenon “the better the economic ranking of a country, the higher the quantity and quality of its biomedical publications”.Citation30

Financial support from public foundations or commercial companies has evolved over time in response to changes in professional codes, laws, and markets. Public funds have given a great push to the development of medical research and public health. Industry-funded science has been widely debated because of the susceptibility to various kinds of biases. Nevertheless, it has played and will continue to play a critical role in the research process. Although this research did not analyze financial support separately, our findings showed that there was a commercial company ranked among the top-ten prolific institutions, which contributed a total of nine articles.

Although researchers were expecting a higher number, only 18% of the papers were review articles, whereas the majority were original research articles, which might be attributable to a preference for referencing experimental evidence rather than review articles or expert opinion.

It has been reported that scientific articles begin to be cited 1 or 2 years after publication and reach a maximum citation rate 7 to 10 years later after publication.Citation26Citation28 It has also been reported that the “older” articles are, the greater the likelihood that they have attained more citations, purely because their citable period was longer. However, in our study, the citation rate gradually rose over the last decade and is indicative of an increasing consideration for the field of COPD.

Authors have to acknowledge that our study has several possible methodological limitations. First and foremost, this survey was restricted with the word “COPD” or “chronic obstructive pulmonary disease” or “chronic obstructive pulmonary diseases” in their titles. In other words, some significant COPD articles published under other titles might not have been included, and it is possible that these were good-quality articles with a high number of citations. Second, the journals have different approaches to accept or reject a submitted manuscript. Thus, particular journals could have stricter selection criteria that might have affected the clinical applicability or quality of their publications. The criteria could be a reason why most top-cited papers were found in one journal. Also, there are some intrinsic problems in using this method alone to evaluate the academic importance of one article, an author’s or authors’ publications, or the performance of a journal overall. First, this type of citation analysis does not account for self-citation, citations in textbooks and lectures, and an author’s or authors’ potential preference to cite articles in the journal in which they seek to publish their work.Citation29 Second, language of publication plays a major role, with an obvious bias for articles published in English language journals. Third, there are biases inherent in the age of the database as any articles published in the 19th or early 20th century would be excluded, which likely causes some true “classic” articles to be excluded. Finally, previous studyCitation16 would tell us that in a scientific community, there is a tendency for adherence to a paradigm. In this context, this would mean that there is “snowball effect” to citations and that other authors are more likely to cite it because of previous citations, rather than for its content or quality. Despite these obvious defects, the data presented here do provide insight into the achievement and development of COPD research over the past decades.

Author contributions

Xiaoyan Jin and Wenchao Gu participated in the study design. Wenchao Gu, Yaping Yuan, Hua Yang, Guangsheng Qi, Xiaoyan Jin, and Jin Yan performed the data extraction and analysis. Hua Yang, Yaping Yuan, Guangsheng Qi and Jin Yan drafted the article. Xiaoyan Jin and Wenchao Gu wrote the manuscript.

Acknowledgments

This study was funded by Outstanding Leaders Training Program of Pudong Health Bureau of Shanghai (Grant No PWR12014-04) and Key Discipline Construction Project of Pudong Health Bureau of Shanghai (Grant No PWZx2014-12).

Disclosure

The authors report no conflicts of interest in this work.

References

  • SimoensSCost-effectiveness of pharmacotherapy for COPD in ambulatory care: a reviewJ Eval Clin Pract20131961004101123590144
  • VestboJHurdSSAgustíAGGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med2013187434736522878278
  • HanMKAgustiACalverleyPMChronic obstructive pulmonary disease phenotypes: the future of COPDAm J Respir Crit Care Med2010182559860420522794
  • RepapiESayersIWainLVWellcome Trust Case Control Consortium; NSHD Respiratory Study Team. Genome-wide association study identifies five loci associated with lung functionNat Genet2010421364420010834
  • AlbertRKConnettJBaileyWCCOPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPDN Engl J Med2011365868969821864166
  • AgustiACalverleyPMCelliBEvaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Characterisation of COPD heterogeneity in the ECLIPSE cohortRespir Res20101112220831787
  • ZhangWJDingWJiangHZhangYFZhangJLNational representation in the plastic and reconstructive surgery literature: a bibliometric analysis of highly cited journalsAnn Plast Surg201370223123422156891
  • YeSXingRLiuJXingFBibliometric analysis of Nobelists’ awards and landmark papers in physiology or medicine during 1983–2012Ann Med201345853253824195599
  • WiysongeCSUthmanOANdumbePMHusseyGDA bibliometric analysis of childhood immunization research productivity in Africa since the onset of the Expanded Program on Immunization in 1974BMC Med2013116623497441
  • WhippleECDixonBEMcGowanJJLinking health information technology to patient safety and quality outcomes: a bibliometric analysis and reviewInform Health Soc Care201338111422657387
  • UgoliniDNeriMCesarioAScientific production in cancer rehabilitation grows higher: a bibliometric analysisSupport Care Cancer20122081629163821881910
  • UgoliniDNeriMCasilliCA bibliometric analysis of scientific production in mesothelioma researchLung Cancer201070212913520170978
  • SunGHBibliometric analysis of health services research in otolaryngology journalsOtolaryngol Head Neck Surg2012147584184722807485
  • RenYWangQJTianLWangCCuiSZhangJBibliometric analysis on lung cancer in China during the period of 2001–2010Thoracic Cancer201234363366
  • NykiforukCIOslerGEViehbeckSThe evolution of smoke-free spaces policy literature: a bibliometric analysisHealth Policy20109711720381188
  • MonyPKSrinivasanKA bibliometric analysis of published noncommunicable disease research in IndiaIndian J Med Res201113423223421911977
  • CheekJGarnhamBQuanJWhat’s in a number? Issues in providing evidence of impact and quality of research(ers)Qual Health Res200616342343516449691
  • JoyceCWKellyJCSugrueCA bibliometric analysis of the 100 most influential papers in burnsBurns2014401303724309203
  • HeinemannMKEditor’s commentaryThorac Cardiovasc Surg201159211421500399
  • GlanvilleJKendrickTMcNallyRCampbellJHobbsFDResearch output on primary care in Australia, Canada, Germany, the Netherlands, the United Kingdom, and the United States: bibliometric analysisBMJ2011342d102821385804
  • D’ArcangeloDGiampietriCFacchianoFFacchianoABAMM: a preliminary bibliometric analysis on melanoma manuscriptsPigment Cell Melanoma Res201326341541723441651
  • CummingsGBiondoPDCampbellDCan the global uptake of palliative care innovations be improved? Insights from a bibliometric analysis of the Edmonton Symptom Assessment SystemPalliat Med2011251718220847088
  • CohenJEChaitonMOPlaninacLCTaking stock a bibliometric analysis of the focus of tobacco research from the 1980s to the 2000sAm J Prev Med201039435235620837286
  • RabeKFHurdSAnzuetoAGlobal Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med2007176653255517507545
  • CelliBRMacNeeWATS/ERS Task ForceStandards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J200423693294615219010
  • HoggJCChuFUtokaparchSThe nature of small-airway obstruction in chronic obstructive pulmonary diseaseN Engl J Med2004350262645265315215480
  • HurstJRVestboJAnzuetoAEvaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
  • MarquisKDebigaréRLacasseYMidthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2002166680981312231489
  • MoedHFNew developments in the use of citation analysis in research evaluationArch Immunol Ther Exp (Warsz)2009571131819219533
  • NielsenFEPublication outcome of research funding by the Danish Heart Foundation 1988–1990Ugeskr Laeger19981603246444648 Danish9719746
  • MarxWSchierHWanitschekMCitation analysis using online databases: feasibilities and shortcomingsScientometrics20015215982
  • GarfieldE100 citation classics from the Journal of the American Medical AssociationJAMA1987257152593537352
  • HallGMBJA citation classics 1945–1992Br J Anaesth1998801469505768
  • SeglenPOWhy the impact factor of journals should not be used for evaluating researchBMJ199731470794985029056804
  • CelliBRCoteCGMarinJMThe body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary diseaseN Engl J Med2004350101005101214999112
  • CalverleyPMAAndersonJACelliBTORCH investigatorsSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
  • AnthonisenNRManfredaJWarrenCPHershfieldESHardingGKNelsonNAAntibiotic therapy in exacerbations of chronic obstructive pulmonary diseaseAnn Intern Med198710621962043492164
  • SiafakasNMVermeirePPrideNBOptimal assessment and management of chronic obstructive pulmonary disease (COPD)Eur Respir J199588139814207489808
  • BrochardLManceboJWysockiMNoninvasive ventilation for acute exacerbations of chronic obstructive pulmonary diseaseN Engl J Med1995333138178227651472
  • KeatingsVMCollinsPDScottDMBarnesPJDifferences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthmaAm J Respir Crit Care Med199615325305348564092
  • SeemungalTADonaldsonGCPaulEABestallJCJeffriesDJWedzichaJAEffect of exacerbation on quality of life in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19981575 Pt 1141814229603117
  • BurgePSCalverleyPMJonesPWSpencerSAndersonJAMaslenTKRandomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trialBMJ200032072451297130310807619
  • TashkinDPCelliBSennSUPLIFT Study InvestigatorsA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
  • DonaldsonGCSeemungalTABhowmikAWedzichaJARelationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax2002571084785212324669
  • BarnesPJChronic obstructive pulmonary diseaseN Engl J Med2000343426928010911010
  • GanWQManSFSenthilselvanASinDDAssociation between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysisThorax200459757458015223864
  • BarnesPJShapiroSDPauwelsRAChronic obstructive pulmonary disease: molecular and cellular mechanismsEur Respir J200322467268814582923
  • CooperJDTrulockEPTriantafillouANBilateral pneumectomy (volume reduction) for chronic obstructive pulmonary diseaseJ Thorac Cardiovasc Surg19951091106116 discussion 116–1197815786
  • CalverleyPPauwelsRVestboJTRial of Inhaled STeroids ANd long-acting beta2 agonists study groupCombined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialLancet2003361935644945612583942
  • BestallJCPaulEAGarrodRGarnhamRJonesPWWedzichaJAUsefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary diseaseThorax199954758158610377201
  • BuistASMcBurnieMAVollmerWMBOLD Collaborative Research GroupInternational variation in the prevalence of COPD (the BOLD Study): a population-based prevalence studyLancet2007370958974175017765523
  • PauwelsRALöfdahlCGLaitinenLALong-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary DiseaseN Engl J Med1999340251948195310379018
  • ScholsAMSlangenJVolovicsLWoutersEFWeight loss is a reversible factor in the prognosis of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19981576 Pt 1179117979620907
  • RiesALKaplanRMLimbergTMPrewittLMEffects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary diseaseAnn Intern Med1995122118238327741366
  • RepineJEBastALankhorstIThe Oxidative Stress Study GroupOxidative stress in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med199715623413579279209
  • CasaburiRMahlerDAJonesPWA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J200219221722411866001
  • ManninoDMBuistASGlobal burden of COPD: risk factors, prevalence, and future trendsLancet2007370958976577317765526
  • RahmanIMorrisonDDonaldsonKMacNeeWSystemic oxidative stress in asthma, COPD, and smokersAm J Respir Crit Care Med19961544 Pt 1105510608887607
  • SethiSEvansNGrantBJMurphyTFNew strains of bacteria and exacerbations of chronic obstructive pulmonary diseaseN Engl J Med2002347746547112181400
  • PlantPKOwenJLElliottMWEarly use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trialLancet200035592191931193510859037
  • SinDDManSFWhy are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary diseaseCirculation2003107111514151912654609
  • SeemungalTARDonaldsonGCBhowmikAJeffriesDJWedzichaJATime course and recovery of exacerbations in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200016151608161310806163
  • AltoseMDRedlineSDeitzCDEffect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary diseaseN Engl J Med2000343261902190911136260
  • VestboJSørensenTLangePBrixATorrePViskumKLong-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trialLancet199935391671819182310359405
  • VinckenWvan NoordJAGreefhorstAPDutch/Belgian Tiotropium Study GroupImproved health outcomes in patients with COPD during 1 yr’s treatment with tiotropiumEur Respir J200219220921611871363
  • GosselinkRTroostersTDecramerMPeripheral muscle weakness contributes to exercise limitation in COPDAm J Respir Crit Care Med199615339769808630582
  • SeemungalTHarper-OwenRBhowmikARespiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200116491618162311719299
  • ItoKItoMElliottWMDecreased histone deacetylase activity in chronic obstructive pulmonary diseaseN Engl J Med2005352191967197615888697
  • SzafranskiWCukierARamirezAEfficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary diseaseEur Respir J2003211748112570112
  • SaettaMDi StefanoATuratoGCD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19981573 Pt 18228269517597
  • AnthonisenNRWrightECHodgkinJEPrognosis in chronic obstructive pulmonary-diseaseAm Rev Respir Dis1986133114203510578
  • HoggJCPathophysiology of airflow limitation in chronic obstructive pulmonary diseaseLancet2004364943570972115325838
  • LandboCPrescottELangePVestboJAlmdalTPPrognostic value of nutritional status in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med199916061856186110588597
  • Soler-CataluñaJJMartinez-GarcíaMARomán SanchezPRSalcedoENavarroMOchandoRSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax2005601192593116055622
  • KuwanoKBoskenCHParéPDBaiTRWiggsBRHoggJCSmall airways dimensions in asthma and in chronic obstructive pulmonary diseaseAm Rev Respir Dis19931485122012258239157
  • LacasseYWongEGuyattGHKingDCookDJGoldsteinRSMeta-analysis of respiratory rehabilitation in chronic obstructive pulmonary diseaseLancet19963489035111511198888163
  • SaintSBentSVittinghoffEGradyDAntibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysisJAMA1995273129579607884956
  • BarnesPJImmunology of asthma and chronic obstructive pulmonary diseaseNat Rev Immunol20088318319218274560
  • NiewoehnerDEErblandMLDeupreeRHEffect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study GroupN Engl J Med1999340251941194710379017
  • BernardSLeBlancPWhittomFPeripheral muscle weakness in patients with chronic obstructive pulmonary-diseaseAm J Respir Crit Care Med199815826296349700144
  • BourbeauJJulienMMaltaisFChronic Obstructive Pulmonary Disease axis of the Respiratory Network Fonds de la Recherche en Santé du QuébecReduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management interventionArch Intern Med2003163558559112622605
  • O’DonnellDEFlügeTGerkenFEffects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPDEur Respir J200423683284015218994
  • PittaFTroostersTSpruitMAProbstVSDecramerMGosselinkRCharacteristics of physical activities in daily life in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2005171997297715665324
  • KeatingsVMJatakanonAWorsdellYMBarnesPJEffects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPDAm J Respir Crit Care Med199715525425489032192
  • O’DonnellDERevillSMWebbKADynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2001164577077711549531
  • WiggsBRBoskenCParéPDJamesAHoggJCA model of airway narrowing in asthma and in chronic obstructive pulmonary diseaseAm Rev Respir Dis19921456125112581595987
  • PauwelsRARabeKFBurden and clinical features of chronic obstructive pulmonary disease (COPD)Lancet2004364943461362015313363
  • HalbertRJNatoliJLGanoABadamgaravEBuistASManninoDMGlobal burden of COPD: systematic review and meta-analysisEur Respir J200628352353216611654
  • MurphyTFSethiSBacterial infection in chronic obstructive pulmonary-diseaseAm Rev Respir Dis19921464106710831416398
  • McSweenyAJGrantIHeatonRKAdamsKMTimmsRMLife quality of patients with chronic obstructive pulmonary-diseaseArch Intern Med198214234734787065785
  • ScholsAMSoetersPBDingemansAMMostertRFrantzenPJWoutersEFPrevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitationAm Rev Respir Dis19931475115111568484624
  • CalverleyPMBoonsawatWCsekeZZhongNPetersonSOlssonHMaintenance therapy with budesonide and formoterol in chronic obstructive pulmonary diseaseEur Respir J200322691291914680078
  • BhowmikASeemungalTASapsfordRJWedzichaJARelation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbationsThorax200055211412010639527
  • LopezADShibuyaKRaoCChronic obstructive pulmonary disease: current burden and future projectionsEur Respir J200627239741216452599
  • AgustiAGNNogueraASauledaJSalaEPonsJBusquetsXSystemic effects of chronic obstructive pulmonary diseaseEur Respir J200321234736012608452
  • TraverGAClineMGBurrowsBPredictors of mortality in chronic obstructive pulmonary disease. A 15-year follow-up studyAm Rev Respir Dis19791196895902453709
  • LambertRKWiggsBRKuwanoKHoggJCParéPDFunctional significance of increased airway smooth muscle in asthma and COPDJ Appl Physiol (1985)1993746277127818365980
  • WagnerPDDantzkerDRDueckRVentilation-perfusion inequality in chronic obstructive pulmonary diseaseJ Clin Invest1977592203216833271
  • BarnesPJCelliBRSystemic manifestations and comorbidities of COPDEur Respir J20093351165118519407051
  • JonesPWBoshTKQuality of life changes in COPD patients treated with salmeterolAm J Respir Crit Care Med19971554128312899105068
  • MontuschiPCollinsJVCiabattoniGExhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokersAm J Respir Crit Care Med20001623 Pt 11175117710988150
  • MahlerDADonohueJFBarbeeRAEfficacy of salmeterol xinafoate in the treatment of COPDChest1999115495796510208192
  • NavaSAmbrosinoNCliniENoninvasive mechanical ventilation in the weaning of patients with respiratory failure due to chronic obstructive pulmonary disease. A randomized, controlled trialAnn Intern Med199812897217289556465
  • CazzolaMMacNeeWMartinezFJAmerican Thoracic SocietyEuropean Respiratory Society Task Force on outcomes of COPDOutcomes for COPD pharmacological trials: from lung function to biomarkersEur Respir J200831241646918238951
  • MonsóERuizJRosellABacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brushAm J Respir Crit Care Med19951524 Pt 1131613207551388
  • RenzettiADMcClementJHLittBDThe Veterans Administration cooperative study of pulmonary function. 3. Mortality in relation to respiratory function in chronic obstructive pulmonary diseaseAm J Med19664111151295328350
  • MaltaisFSimardAASimardCJobinJDesgagnésPLeBlancPOxidative capacity of the skeletal muscle and lactic acid kinetics during exercise in normal subjects and in patients with COPDAm J Respir Crit Care Med199615312882938542131
  • WilsonDORogersRMWrightECAnthonisenNRBody weight in chronic obstructive pulmonary disease. The National Institutes of Health Intermittent Positive-Pressure Breathing TrialAm Rev Respir Dis19891396143514382658702
  • SeneffMGWagnerDPWagnerRPZimmermanJEKnausWAHospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary diseaseJAMA199527423185218577500534
  • ScanlonPDConnettJEWallerLALung Health Study Research GroupSmoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health StudyAm J Respir Crit Care Med20001612 Pt 138139010673175
  • PaggiaroPLDahleRBakranIFrithLHollingworthKEfthimiouJMulticentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study GroupLancet199835191057737809519948
  • CelliBRThomasNEAndersonJAEffect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH studyAm J Respir Crit Care Med2008178433233818511702
  • VestboJPrescottELangePAssociation of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study GroupAm J Respir Crit Care Med19961535153015358630597
  • PapiABellettatoCMBraccioniFInfections and airway inflammation in chronic obstructive pulmonary disease severe exacerbationsAm J Respir Crit Care Med2006173101114112116484677
  • SaettaMTuratoGMaestrelliPMappCEFabbriLMCellular and structural bases of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200116361304130911371392
  • Di FranciaMBarbierDMegeJLOrehekJTumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19941505 Pt 1145314557952575
  • ScholsAMBuurmanWAStaal van den BrekelAJDentenerMAWoutersEFEvidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary diseaseThorax19965188198248795671
  • RahmanIAdcockIMOxidative stress and redox regulation of lung inflammation in COPDEur Respir J200628121924216816350
  • SethiSMurphyTFBacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art reviewClin Microbiol Rev200114233636311292642
  • WedzichaJACalverleyPMSeemungalTAHaganGAnsariZStockleyRAINSPIRE InvestigatorsThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med20081771192617916806
  • DekhuijzenPNAbenKKDekkerIIncreased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19961543 Pt 18138168810624
  • DonohueJFvan NoordJABatemanEDA 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterolChest20021221475512114338
  • NishimuraKIzumiTTsukinoMOgaTDyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPDChest200212151434144012006425
  • MenezesAMPerez-PadillaRJardimJRPLATINO TeamChronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence studyLancet200536695001875188116310554
  • PatelISSeemungalTAWilksMLloyd-OwenSJDonaldsonGCWedzichaJARelationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbationsThorax200257975976412200518
  • O’DonnellDELamMWebbKAMeasurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19981585 Pt 1155715659817708
  • AaronSDVandemheenKLFergussonDCanadian Thoracic Society/Canadian Respiratory Clinical Research ConsortiumTiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trialAnn Intern Med2007146854555517310045
  • WeitzenblumEHirthCDucoloneAMirhomRRasaholinjanaharyJEhrhartMPrognostic value of pulmonary artery pressure in chronic obstructive pulmonary diseaseThorax198136107527587330793
  • KannerREAnthonisenNRConnettJELung Health Study Research GroupLower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health studyAm J Respir Crit Care Med2001164335836411500333